Moffitt Launches New Mesothelioma Clinical Trials in Tampa

The mesothelioma program at the Moffitt Cancer Center in Tampa opened two new clinical trials recently, expanding efforts to provide patients throughout the state with more treatment options. Both mesothelioma-specific, phase II trials are designed as second-line therapies involving options that have shown success with other types of cancer. “If a patient is willing and able, we would encourage them to look at these opportunities,” said Dr. Tawee Tanvetyanon, Moffitt medical oncologist and mesothelioma specialist. “People look to trials today because they can find the newest, and sometimes the best, treatment before it is available everywhere.” The two new clinical trials at Moffitt, involving unresectable pleural mesothelioma, are exploring the effectiveness of: Transarterial chemoperfusion treatment with cisplatin, methotrexate and gemcitabine. Mesothelin-targeting, antibody drug anetumab ravtansine (BAY 94-9343). Moffitt also is continuing its role in the multicenter clinical trial of immunotherapy drug CRS-207. That trial measures the drug’s ability to stimulate a patient’s immune system when fighting unresectable mesothelioma. Early results using the genetically modified version of listeria are promising and will soon be published. “Progress is being made in the treatment of mesothelioma. It’s benefiting now from advances and successes with other cancers,” Tanvetyanon told Asbestos.com. “These trials are about advancing ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Research & Clinical Trials Source Type: news